cancer

Health By Pratibha Gopalakrishna

New research shows older adults are still often excluded from clinical trials

Biotech By Matthew Herper

‘The largest application we can imagine’: Illumina and Grail CEOs defend their deal to investors

Video Chat By Adam Feuerstein

STAT Virtual Event: The ESMO Recap, Live!

Health Tech By Rebecca Robbins

When AI is the opposite of sinister: An MIT researcher is held up as model of how algorithms can benefit humanity

First Opinion By Steven Petrow

Cancer survivor: Don’t forget that accolade when it comes to Ruth Bader Ginsburg’s remarkable life

Biotech By Matthew Herper

With Grail in its sights, Illumina pursues grand vision that could reshape the business of cancer diagnoses

Biotech By Matthew Herper

With a detailed rundown, Pfizer seeks to paint a picture of a research turnaround

Biotech By Adam Feuerstein and Matthew Herper

Inside Gilead’s $21 billion purchase of Immunomedics: Lamb chops, steak, and a chance for transformation

Pharma By Kate Sheridan

23andMe’s next challenge: ensuring its customers can get drugs developed with their data

Biotech By Kate Sheridan

Liquid biopsy startup Grail, in filing for IPO, lays out investments and plans for growth

Health Tech By Casey Ross

Can AI improve cancer diagnosis in real patients? The U.S. military has enlisted Google to find out

Biotech By Adam Feuerstein

Blueprint Medicines wins U.S. approval for genetically targeted lung cancer drug

Biotech By Jonathan Chan

‘The race is on’: China’s I-Mab gets boost from AbbVie to develop a new cancer immunotherapy

First Opinion By Lydia A. Flier, Gabriela Rico, and Yamicia D. Connor

Did disparities kill the king of Wakanda? Chadwick Boseman and changing landscape of colon cancer demographics

Biotech By Elizabeth Cooney

Foundation Medicine wins FDA approval for liquid biopsy able to detect mutations in multiple cancers 

In the Lab By Meghana Keshavan

New research tabs a natural byproduct of metabolism as a potent trigger of cancer spread

Biotech By Matthew Herper

Turning Point releases positive data for targeted cancer drug, points to more rapid FDA filing

First Opinion By Norman E. Sharpless

Lung cancer deaths are declining faster than new cases. Advances in treatment are making the difference

Pharmalot By Ed Silverman

Pharmalittle: FDA approves another Duchenne muscular dystrophy drug; European orphan drug incentives questioned

Health By Elizabeth Cooney

Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment

Health By Associated Press

Telemedicine shines during pandemic but will glow fade?

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca strikes first Covid-19 deal with a Chinese company; vaccine trials face distrust from minority groups

Health By Elizabeth Cooney

New cancer diagnoses fell sharply as the coronavirus pandemic first hit

Pharmalot By Ed Silverman

Pharmalittle: Global supply chain not ready for Covid-19 vaccines; Moderna may price its vaccine at up to $60

Pharma By Matthew Herper

Cancer drug is the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration